Analysis

Pharma Technology Focus – Issue 57

Pharma Technology Focus – Issue 57

Turning to turmeric: exciting drug candidate or another dead end?

Turning to turmeric: exciting drug candidate or another dead end?

BlueRock Therapeutics: Ontario’s home-grown stem cell contender

BlueRock Therapeutics: Ontario’s home-grown stem cell contender

Takeda turns its focus overseas

Takeda turns its focus overseas

Learning from tragedy: safety and dosing in first-in-human trials

Learning from tragedy: safety and dosing in first-in-human trials

February's top stories: Takeda's $5.2bn acquisition, Sanofi €270m cell culture facility investment

February's top stories: Takeda's $5.2bn acquisition, Sanofi €270m cell culture facility investment

Is US drug manufacturing homeward bound?

Is US drug manufacturing homeward bound?

Using shark antibodies to treat Alzheimer’s disease

Using shark antibodies to treat Alzheimer’s disease

How an Alzheimer’s drug turned tooth regenerator could unlock regenerative medicine

How an Alzheimer’s drug turned tooth regenerator could unlock regenerative medicine

Moving mountains: balancing safety and speed in drug development

Moving mountains: balancing safety and speed in drug development

Medicines Discovery Catapult: improving collaborative drug discovery in the UK

Medicines Discovery Catapult: improving collaborative drug discovery in the UK

Therapeutic orphans: child-friendly drugs and the quest for adherence

Therapeutic orphans: child-friendly drugs and the quest for adherence

Nigeria’s HIV ‘breakthrough’: separating truth from hope

Nigeria’s HIV ‘breakthrough’: separating truth from hope

A peptide to prevent pre-diabetes

A peptide to prevent pre-diabetes

Pharma Technology Focus – Issue 56

Pharma Technology Focus – Issue 56

Why the UK NHS needs clinical research

Why the UK NHS needs clinical research

The Hive: new incubator makes a beeline for non-traditional pharma companies

The Hive: new incubator makes a beeline for non-traditional pharma companies

BenevolentAI: using artificial intelligence to speed up drug discovery

BenevolentAI: using artificial intelligence to speed up drug discovery

January's top stories: J&J to acquire Actelion for $30bn, Takeda to acquire ARIAD for $5.2bn

January's top stories: J&J to acquire Actelion for $30bn, Takeda to acquire ARIAD for $5.2bn

Tapping digital technologies to improve drug adherence

Tapping digital technologies to improve drug adherence

Takeda and Ovid to Co-develop Drug for Rare Pediatric Epilepsies

Takeda and Ovid to Co-develop Drug for Rare Pediatric Epilepsies
cachename:Featurescachekey:rd-1665407042_727740091_rd-488908060_1460672566_ap1460672566_727740091_-2004945256